CLASS II ONGOING Drug recall · Reported 11 Mar 2026 · FDA Enforcement Report

Metoprolol Succinate Extended-Release Tablets, 25 mg bottles recalled

Teva Pharmaceuticals USA is recalling Metoprolol Succinate Extended-Release Tablets, 25 mg bottles (, distributed nationwide in the US. The recall was initiated on 29 Jan 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: a) 0715J251, Exp.: 12/2026; 0716J251, Exp.: 01/2027; 0717J251, Exp.: 01/2027; b) 0715J252, Exp.: 12/2026; 0716J252, Exp.: 01/2027, 0717J252, Exp.: 01/2027.
NDC45963-676, 45963-709, 45963-677, 45963-678
Quantity recalled18,780 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0354-2026
FDA event ID
98348
Recalling firm
Teva Pharmaceuticals USA, Parsippany, NJ
Manufacturer
Actavis Pharma, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
29 Jan 2026
FDA classified
27 Feb 2026
Reported
11 Mar 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

29 Jan 2026Recall initiated by company
27 Feb 2026Classified by FDA+29 days
11 Mar 2026Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: 45963-709-11) and 1,000 tablets bottles (NDC: 45963-709-96), Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Is Metoprolol Succinate Extended-Release Tablets, 25 mg bottles ( recalled?

Yes. Teva Pharmaceuticals USA recalled Metoprolol Succinate Extended-Release Tablets, 25 mg bottles ( on 29 Jan 2026. The recall is Class II and its status is Ongoing. Recall number D-0354-2026.

Why was it recalled?

Failed Dissolution Specifications

Which lots are affected?

Lot#: a) 0715J251, Exp.: 12/2026; 0716J251, Exp.: 01/2027; 0717J251, Exp.: 01/2027; b) 0715J252, Exp.: 12/2026; 0716J252, Exp.: 01/2027, 0717J252, Exp.: 01/2027.

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Teva Pharmaceuticals USA

All 84

Other Metoprolol recalls

All 30